Monthly Healthcare Review September 2017 IPOs The following table includes the medical devices, biotechnology, pharmaceuticals, and healthcare IPO pricings, filings and withdrawals announced over the previous month.

Last Last Financing Financing Company Name HQ Location Description Lead Manager Date Size (Millions) Developer of kinase-inhibiting drugs, including tumor-targeted therapies and immuno- Deciphera (DCPH) 28-Sep-17 Waltham, MA targeted therapies, designed to treat cancer and immunological diseases. 127.50 JPM Securities

Source: Pitchbook Compiled by: Lea Keller and Morgan Reape 1 Monthly Healthcare Review September 2017 Private Equity Placements and Venture Capital Rounds The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month. Last Last Financing Company Name Financing HQ Location Round Description Investor(s) Size Date (Millions) Sunderland, United Developer of proprietary diagnostic immunoassays for the detection of Undisclosed Arquer Diagnostics 1-Sep-17 Kingdom Later Stage VC prostate and bladder cancer using urine samples. 2.76 Investors

Mid Atlantic Bio Developer of small molecule antiviral therapeutics that target non-viral Angels, Keiretsu human proteins, known as sirtuins, and enhance their natural ability to Forum, Undisclosed Forge Life Science 1-Sep-17 Doylestown, PA Early Stage VC fight powerful infections. 3.37 Investors Provider of services designed to bridge the gap between discoveries in the life sciences and meaningful real-world applications. The company's program de-risks transfers of tech assets from top research institutes, enabling them to build a portfolio of high-ROI biotech investments. The company's flagship program - Nivien Therapeutics - is a venture-backed Accelerator/ oncology startup developing a novel platform to enhance IO-chemo General Biotechnologies 1-Sep-17 Cambridge, MA Incubator combo therapies for treatment-resistant cancers. 0.25 IndieBio Provider of biotechnology research services focused on clinical development activities in orphan pediatric oncology treatment with a focus VIB, Oncurious 1-Sep-17 Leuven, Belgium Early Stage VC on preclinical research and drug development programs. 2.48 ThromboGenics Provider of a high-throughput drug-sensitivity assay kit for precision medicine to pre-test a number of drug combinations on a cancer patient's Accelerator/ biopsy samples and allow doctors to treat patients with personalized drug ImpriMed 4-Sep-17 Palo Alto, CA Incubator combinations. Undisclosed Pear Ventures Bio/Med Investor Network, Georgia Research Alliance, Robert Thomas, Undisclosed Accuitis 5-Sep-17 Cumming, GA Angel Developer and marketer of pharmaceuticals for dermatological diseases. 1.75 Investors

Source: Pitchbook Compiled by: Lea Keller and Morgan Reape 2 Monthly Healthcare Review September 2017 Private Equity Placements and Venture Capital Rounds The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month. Last Last Financing Company Name Financing HQ Location Round Description Investor(s) Size Date (Millions)

Boehringer Ingelheim Venture Fund, BioMedPartners, Helsinn Investment Fund, Schroder Adveq, High-Tech Geneva, Gründerfonds, VI Amal Therapeutics 5-Sep-17 Switzerland Early Stage VC Developer of novel, peptide-based therapeutic cancer vaccines. 9.12 Partners

Pivotal bioVenture Developer of antibacterial therapeutics targeting gram-negative infections, Partners, Sofinnova such as pneumonia, infections of the blood, urinary tract infections and Ventures, TPG Entasis Therapeutics 5-Sep-17 Waltham, MA Early Stage VC infections following surgery. 31.90 Biotech

LifeCare Partners, Life Sciences Partners, IBG Beteiligungsgesellsch aft Sachsen-Anhalt, Bayern Kapital, High-Tech Gründerfonds, Bmp Planegg- Provider and developer of small molecule immune modulators that block Beteiligungsmanage Martinsried, T-helper type 1- and type 17-mediated immune and autoimmune responses ment, Undisclosed Immunic Therapeutics 5-Sep-17 Germany Early Stage VC to treat conditions including inflammatory bowel disease and psoriasis. 37.44 Investors

Source: Pitchbook Compiled by: Lea Keller and Morgan Reape 3 Monthly Healthcare Review September 2017 Private Equity Placements and Venture Capital Rounds The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month. Last Last Financing Company Name Financing HQ Location Round Description Investor(s) Size Date (Millions) Theil Capital, Founders Fund, IronBridge Capital, Abstract Capital, Undisclosed Rational Vaccines 5-Sep-17 Springfield, IL Seed Round Developer of herpes simplex virus vaccines and serology tests. 8.20 Investors Provider of manufacturing informatics software and process optimization, manufacturing IP, and compliance services to drug manufacturers and Undisclosed Skyland Analytics 5-Sep-17 Boulder, CO Early Stage VC their contract manufacturing organizations. 0.89 Investors

Developer of vaccines and immunotherapeutic drugs integrating rational Schlieren, molecular design, chemical synthesis, and a proprietary synthetic particle Undisclosed Virometix 5-Sep-17 Switzerland Angel technology to prevent and treat infections and chronic human diseases. 1.24 Investors Developer and manufacturer of a unique in-vitro diagnostic system based on proprietary gel-drop micro-array technology for rapid, reliable, Undisclosed Akonni Biosystems 6-Sep-17 Frederick, MD Later Stage VC multiplexed analysis in a low-cost format. 4.00 Investors Developer of CardeaScreen, a body-worn sensing and computing monitor for applications in cardiology, respiratory assessments, and other complex Undisclosed Cardiac Insight 6-Sep-17 Kirkland, WA Later Stage VC disease states. 4.50 Investors Developer of advanced gene editing therapeutics created to offer safe and ARTIS Ventures, efficacious medicines that will eradicate or disrupt viral genes in human Undisclosed Excision 6-Sep-17 New York, NY Seed Round patients. 10.00 Investors Developer of a multimarker prognostic and predictive test that identifies Sequoia Capital risk of recurrence in patients with hormone receptor positive breast cancer India, Artiman OncoStem Diagnostics 6-Sep-17 Bangalore, India Early Stage VC from stage 1 through stage 3A. 6.00 Ventures Alta Life Sciences, HealthEquity, Developer of peptide therapeutics targeting the Myc oncogene, a central Undisclosed Peptomyc 6-Sep-17 Barcelona, Spain Early Stage VC function in cancer cell survival, designed to treat cancer. 4.96 Investors

Source: Pitchbook Compiled by: Lea Keller and Morgan Reape 4 Monthly Healthcare Review September 2017 Private Equity Placements and Venture Capital Rounds The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month. Last Last Financing Company Name Financing HQ Location Round Description Investor(s) Size Date (Millions) Secondary Developer of a three-dimensional printed pharmaceutical platform Transaction - designed to offer pharmaceuticals used to treat epilepsy and other central Undisclosed Aprecia Pharmaceuticals 7-Sep-17 Langhorne, PA Private nervous system disorders. Undisclosed Investors Developer of non-invasive vagus nerve stimulation therapies designed to treat multiple conditions in neurology, psychiatry, gastroenterology, and Undisclosed electroCore 7-Sep-17 Bernards, NJ Later Stage VC other fields. 36.00 Investors

Lilly Asia Ventures, GV, Trinitas Capital (Beijing), Alexandria Venture Investments, Versant Venture Management, The Column Group, Clarus Ventures, Operator of an immuno-oncology platform designed to develop next- Frazier Healthcare Gritstone Oncology 7-Sep-17 Emeryville, CA Early Stage VC generation personalized cancer therapeutics. 92.70 Partners Developer of eye-tracking metrics and devices designed to give medical Undisclosed Sync Think 7-Sep-17 Boston, MA Early Stage VC professionals objective metrics for visual attention. 1.92 Investors Sequoia Capital China, Temasek Holdings, Amgen Ventures, Ally Bridge Group, Provider of a global genomics platform created to provide genomic Yunfeng Capital, WuXi NextCODE 7-Sep-17 Cambridge, MA Early Stage VC sequence data. 240.00 3W Partners

Source: Pitchbook Compiled by: Lea Keller and Morgan Reape 5 Monthly Healthcare Review September 2017 Private Equity Placements and Venture Capital Rounds The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month. Last Last Financing Company Name Financing HQ Location Round Description Investor(s) Size Date (Millions)

Foresite Capital, Bain Capital, Redmile Group, Provider of a therapeutic treatment designed to maximize systemic Cormorant Asset immune activation, in particular to tumor neoantigens, through robust viral Management, Atlas mediated immunogenic tumor cell killing and the delivery of optimal Venture, Forbion combinations of immune activating proteins to the tumor and draining Capital Partners, Replimune 8-Sep-17 Woburn, MA Early Stage VC lymph nodes. 55.00 Omega Funds GV, Novartis, AstraZeneca, Cathay Ventures, Joseph Gunnar and Co, through their Buttonwood Alpha Fund, Crystal Horizon Investments, Pinemount Investments, Pacific Venture Developer of a novel approach for the delivery of large drug molecules, Opportunity Fund, including peptides, proteins, and antibodies, by converting injectable drugs Bossa Nova Rani Therapeutics 9-Sep-17 San Jose, CA Later Stage VC into oral pills. 39.00 Investimentos Developer of general anesthetic products and pain drugs to help hospitals Undisclosed Expanesthetics 11-Sep-17 Davis, CA Angel and surgery centers manage surgical pain. 1.68 Investors GeneChem Management, Developer of cellular therapies created to revolutionize the treatment of Sanderling Ventures, SpecificiT Pharma 11-Sep-17 Montreal, Canada Seed Round hematological cancers. Undisclosed Accel-Rx

Source: Pitchbook Compiled by: Lea Keller and Morgan Reape 6 Monthly Healthcare Review September 2017 Private Equity Placements and Venture Capital Rounds The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month. Last Last Financing Company Name Financing HQ Location Round Description Investor(s) Size Date (Millions) Arch BioPartners Developer of diagnosis and treatment methods for acute and chronic Undisclosed (ARCH) 12-Sep-17 Toronto, Canada PIPE diseases. 0.20 Investors

Illumina Ventures, Developer of a DNA synthesis technology that overcomes the current Sofinnova Partners, inefficiencies of synthetic DNA production and enables affordable, rapid, Merck Ventures, high-quality, and high-throughput production of synthetic biology tools, Kurma Partners, DNA Script 12-Sep-17 Paris, France Early Stage VC such as oligonucleotides, genes, pathways, and genomes. 12.99 Idinvest Partners

Green Dot Labs 12-Sep-17 Boulder, CO Early Stage VC Producer of marijuana for licensed medical marijuana centers. 3.30 Tuatara Capital Developer of gamma-ray imaging spectrometers for use in various Undisclosed H3D 12-Sep-17 Ann Arbor, MI Angel applications, including proton cancer therapy. 2.80 Investors Developer of translational and immune modulating drugs to cure Undisclosed Kineta 12-Sep-17 Seattle, WA Later Stage VC autoimmune diseases, viral diseases, and severe pain. 5.50 Investors

Shenzhen Cowin Venture Capital Investments, Fosun Industrial Holdings, Cloudstone Venture, Provider of rapid, easy-to-use, and ultra-high multiplex PCR-based target Heda Ventures, Paragon Genomics 12-Sep-17 Hayward, CA Early Stage VC enrichment services for the next-generation sequencing markets. 8.00 Wisemont Capital

Source: Pitchbook Compiled by: Lea Keller and Morgan Reape 7 Monthly Healthcare Review September 2017 Private Equity Placements and Venture Capital Rounds The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month. Last Last Financing Company Name Financing HQ Location Round Description Investor(s) Size Date (Millions)

Aisling Capital, American International Group, Cormorant Capital, Kohlberg Kravis Roberts, Perceptive Advisors, Viking PE Growth/ Global Investors, BridgeBio 13-Sep-17 Palo Alto, CA Expansion Developer of genetically targeted therapies intended to treat rare diseases. 135.00 Janus Capital Group

Club degli Investitori, ProVation Medical, Ferragamo Developer of a gene transfer strategy intended to provide autologous Finanziaria, hematopoietic stem cells to target interferon-α expression to tumor- Undisclosed Genenta Science 13-Sep-17 Milan, Italy Angel infiltrating macrophages. 8.27 Investors

Source: Pitchbook Compiled by: Lea Keller and Morgan Reape 8 Monthly Healthcare Review September 2017 Private Equity Placements and Venture Capital Rounds The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month. Last Last Financing Company Name Financing HQ Location Round Description Investor(s) Size Date (Millions)

Fall Line Capital, Seed 2 Growth Ventures, Lewis and Clark Ventures, Macro Capital Investments, Kodiak Venture Partners, Spruce Capital Partners, Syngenta Ventures, Developer of a cell-free bio-processing platform designed to ensure Undisclosed GreenLight Biosciences 13-Sep-17 Medford, MA Later Stage VC sustainable global development with bio-processed RNA. 18.00 Investors Ben Franklin Technology Partners, Developer of a software platform that uses predictive analytics to unify Undisclosed Oncora Medical 13-Sep-17 Philadelphia, PA Seed Round data on radiation oncology. 1.89 Investors Balderton Capital, 360 Capital Partners, Saint Sulpice, Invoke Capital, Sophia Genetics 13-Sep-17 Switzerland Later Stage VC Developer of a clinical genomics analysis platform. 30.00 Alychlo

Developer of a next generation DNA sequencing therapy created to detect Undisclosed TwinStrand Biosciences 13-Sep-17 Seattle, WA Seed Round ultra-rare variants that are invisible by other sequencing approaches. 5.28 Investors Developer of a targeted immunotherapy created to not only directly kill tumor cells without detrimental effects on normal tissues, but also Longview modulate the adaptive immune response to attack tumor cells anywhere in International, Duke Grid Therapeutics 14-Sep-17 Durham, NC Early Stage VC the body. Undisclosed University

Source: Pitchbook Compiled by: Lea Keller and Morgan Reape 9 Monthly Healthcare Review September 2017 Private Equity Placements and Venture Capital Rounds The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month. Last Last Financing Company Name Financing HQ Location Round Description Investor(s) Size Date (Millions)

Developer of engineered antibody fragments for diagnostic imaging and radio immunotherapy intended to leverage the exquisite specificity of Undisclosed ImaginAb 14-Sep-17 Inglewood, CA Later Stage VC monoclonal antibodies to create precise images of disease activity. 7.67 Investors Undisclosed Micell Technologies 14-Sep-17 Durham, NC Later Stage VC Developer of drug-delivery systems for cardiovascular diseases. 61.78 Investors Developer of glycopolymer-based therapeutics to treat and alter the progression of pulmonary diseases by disrupting mucus accumulation and Undisclosed Synspira 14-Sep-17 Boston, MA Angel bacterial bio-film invasion. 8.24 Investors Secondary Saint Petersburg, Transaction - Developer of transdermal, sublingual, and nasal delivery technologies for Apotheca Biosciences 15-Sep-17 FL Private precise and controlled dosing of cannabinoids. Undisclosed FutureLand Provider of a drug discovery platform that combines quantum physics and GTN (Generative London, United Accelerator/ machine learning algorithms to transform search and discovery of patient- Tensorial Networks) 15-Sep-17 Kingdom Incubator centered drugs. 0.10 Entrepreneur First

Developer of improved methods to stimulate a patient's immune system Undisclosed Orbis Health Solutions 15-Sep-17 Greenville, SC Angel and enhance its ability to recognize and destroy disease entities. 2.80 Investors Provider of oncology-based diagnostic tests and clinical laboratory services Undisclosed Provista Diagnostics 15-Sep-17 New York, NY Later Stage VC to the pharmaceutical and biotechnology industries. 16.04 Investors Pangaea Ventures, Endure Capital, Pallasite Ventures, Relentless Pursuit Provider of a 3D bioprinting technology capable of creating human tissues Partners, on demand, primarily for human tissue models in pre-clinical drug Undisclosed Aspect Biosystems 18-Sep-17 Vancouver, Canada Early Stage VC discovery. Undisclosed Investors

Source: Pitchbook Compiled by: Lea Keller and Morgan Reape 10 Monthly Healthcare Review September 2017 Private Equity Placements and Venture Capital Rounds The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month. Last Last Financing Company Name Financing HQ Location Round Description Investor(s) Size Date (Millions)

Menlo Ventures, AME Cloud Ventures, BioGenerator, Ascension Ventures, iSelect Fund, Wilson Sonsini Goodrich & Rosati, Stanford, Data Collective, 7percent ventures, Operator of a biotechnology company that provides full genome Refactor Capital, SV sequencing, sequence assembly, expressed sequence tagging, gene Tech Ventures, alignments, and sequence analysis to enable detection and diagnosis of David Lee, Jude diseases and translate next-generation sequencing-based technologies into Gomila, Paul stable and complete end-to-end product solutions through R&D Bucheit, Y Cofactor Genomics 18-Sep-17 Saint Louis, MO Later Stage VC developments that combine molecular, sequencing, and bioinformatics. 18.00 Combinator Abingdon, United Developer of immunotherapeutic drugs intended to exploit and enhance Bill & Melinda Immunocore 18-Sep-17 Kingdom Later Stage VC the body's own immune system. 40.00 Gates Foundation

Developer of a R&D engine to systematically create, discover, and develop Flagship Pioneering, interventions that activate metabolic processes in the microbiome to treat Undisclosed Kaleido BioSciences 18-Sep-17 Bedford, MA Early Stage VC disease and maintain health. 37.10 Investors

Source: Pitchbook Compiled by: Lea Keller and Morgan Reape 11 Monthly Healthcare Review September 2017 Private Equity Placements and Venture Capital Rounds The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month. Last Last Financing Company Name Financing HQ Location Round Description Investor(s) Size Date (Millions)

WuXi Healthcare Ventures, Foresite Capital, GV, Arch Venture Partners, Boyu Capital, Blue Pool Capital, Merck Ventures, Developer of novel drugs by exploiting small molecule evolution in fungi Alexandria Venture LifeMine Therapeutics 18-Sep-17 Cambridge, MA Early Stage VC to discover game-changing therapeutics. 55.00 Investments Hatteras Venture Partners, Atlas Venture, GV, Remeditex Developer of epigenetic drugs for the treatment of cognitive disorders and Ventures, Third Rodin Therapeutics 18-Sep-17 Cambridge, MA Early Stage VC diseases of the brain. 27.00 Point Ventures Atlas Venture, BioGenerator, Lightstone Developer of therapeutics created to treat patients with neurological Ventures, AbbVie Disarm 19-Sep-17 Cambridge, MA Early Stage VC diseases by preventing axonal degeneration. 30.00 Ventures Developer of an autologous and allogeneic drug pipeline designed for the Korea Investment treatment of autoimmune and inflammatory conditions that involve over- Partners, Hadasit Enlivex Therapeutics 19-Sep-17 Jerusalem, Israel Later Stage VC expression or hyper-expression of cytokines. 8.00 Bio Holding

Barranquilla, PE Growth/ Manufacturer of medicines with activities ranging from product International Procaps 19-Sep-17 Colombia Expansion development to pharmaceutical production and distribution. Undisclosed Finance Corporation

Source: Pitchbook Compiled by: Lea Keller and Morgan Reape 12 Monthly Healthcare Review September 2017 Private Equity Placements and Venture Capital Rounds The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month. Last Last Financing Company Name Financing HQ Location Round Description Investor(s) Size Date (Millions)

White Cloud Capital, Amadeus Capital Partners, Sofinnova Partners, London, United Developer of a language and software platform designed to bring end-to- SOSV, Bioeconomy Synthace 19-Sep-17 Kingdom Later Stage VC end digitization to biotechnology. 9.47 Capital Undisclosed Tolremo Therapeutics 19-Sep-17 Zurich, Switzerland Seed Round Developer of novel targeted therapeutics for the treatment of cancer. 2.49 Investors Biomark Diagnostics Developer of advanced stage diagnostic technologies intended to increase Undisclosed (BUX) 20-Sep-17 Richmond, Canada PIPE the accuracy of cancer diagnostics. 0.66 Investors Developer of targeted therapeutic products for ovarian and other Critical Outcome gynecological cancers that help restore normal cell signaling in cancer with Undisclosed Technologies (COT) 20-Sep-17 London, Canada PIPE p53 mutations. 1.50 Investors

Lumira Capital, Pharmascience, Cipher Pharmaceuticals, Inveready Technology Investment Group, Operator of a clinical-stage firm intended to develop dermatological and Yissum, Undisclosed Edesa Biotech 20-Sep-17 Markham, Canada Early Stage VC anorectal drugs. 7.00 Investors Developer of a health informatics-based tool intended to accelerate the discovery, development, and delivery of personalized medicine for cancer M2gen 20-Sep-17 Tampa, FL Later Stage VC therapies. 75.00 Hearst Health

Source: Pitchbook Compiled by: Lea Keller and Morgan Reape 13 Monthly Healthcare Review September 2017 Private Equity Placements and Venture Capital Rounds The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month. Last Last Financing Company Name Financing HQ Location Round Description Investor(s) Size Date (Millions)

Elements Capital and WI Harper Group, KTB Network, Kleiner Perkins Caufield & Byers, Johnson & Johnson Innovation - JJDC, WuXi Developer of a bio-pharmaceutical platform designed to improve the Healthcare pharmacokinetics and safety profiles of existing drugs and find potential Investment new indications, enabling doctors to reduce damage to the mitochondria Consulting XW Laboratories 20-Sep-17 Wuhan, China Early Stage VC and treat neurological disorders. 17.50 (Shanghai) Precision Health Intelligence 21-Sep-17 New York, NY Corporate Developer of an artificial intelligence platform focused on oncology. 20.00 Symphony AI Developer of antibody therapeutics designed to treat cancer, fibrosis, and Undisclosed Tilos Therapeutics 21-Sep-17 Cambridge, MA Seed Round related disorders. 3.05 Investors

Chemelot Ventures, Limburg Business Development Fund, Maastricht, Provider of biotechnology research and development services focused on Undisclosed TripleMed 21-Sep-17 Netherlands Later Stage VC the treatment of aortic aneurysms. 2.36 Investors

Source: Pitchbook Compiled by: Lea Keller and Morgan Reape 14 Monthly Healthcare Review September 2017 Private Equity Placements and Venture Capital Rounds The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month. Last Last Financing Company Name Financing HQ Location Round Description Investor(s) Size Date (Millions)

Legend Capital, China International Capital Corporation, Gefeiyueren, Operator of a medical contract research organization developing chemical Dachen Chuanglian, Bellen 22-Sep-17 Beijing, China Later Stage VC synthesis for innovative chemical drugs. 37.44 Dianjing Shijie

DelMar Pharmaceuticals Developer of therapies used for the treatment of brain cancer, cell lung Undisclosed (DMPI) 22-Sep-17 Vancouver, Canada PIPE cancer, and ovarian cancer. 10.00 Investors

MicroPort Scientific, Developer of an office-based, portable MRI with cellular spatial resolution Keiretsu Forum, and real-time targeted biopsy and treatment tools created to transform Undisclosed Promaxo 22-Sep-17 Rockville, MD Early Stage VC prostate cancer disease management. 3.79 Investors New Enterprise Developer of a healthcare data analytics platform designed to enable Associates, Tempus Health 22-Sep-17 Chicago, IL Later Stage VC personalized cancer care. 70.00 Revolution Group Maven Capital Developer of new antibody drug conjugates and anti-cancer therapies that Partners, Finance Saint Asaph, United PE Growth/ target specific cancer cells where they are internalized prior to release of Wales, Seneca ADC Biotechnology 25-Sep-17 Kingdom Expansion the drugs. Undisclosed Partners UK Athyrium Capital Management, Bessemer Venture Developer of enzyme-based nutritional products that help in breaking Partners, down complex foods to manage disease for infants, older adults, and Undisclosed Alcresta Therapeutics 25-Sep-17 Newton, MA Later Stage VC patients battling acute or chronic conditions. 60.89 Investors

Source: Pitchbook Compiled by: Lea Keller and Morgan Reape 15 Monthly Healthcare Review September 2017 Private Equity Placements and Venture Capital Rounds The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month. Last Last Financing Company Name Financing HQ Location Round Description Investor(s) Size Date (Millions) Operator of a health technology company created to diagnose brain Data Collective, disorders using an efficient and radiation-free approach that involves Undisclosed BrainSpec 25-Sep-17 Boston, MA Early Stage VC software and magnetic resonance spectroscopy. 1.73 Investors Developer of an integrated genetic computational system that alters crucial cellular processes, including transcription, splicing, polyadenylation, and Khosla Ventures, Deep Genomics 25-Sep-17 Toronto, Canada Early Stage VC translation, leading to effective therapies. 13.00 True Ventures

Johnson & Johnson Innovation - JJDC, Fight Against Cancer Innovation Trust, Genesys Capital, HealthCap, Adams Street Partners, Seroba Life Sciences, Developer of novel targeted alpha therapeutics for chemotherapy resistant Varian Medical cancers created to leverage radioactivity in relatively low doses to attack Systems, TPG Fusion Pharmaceuticals 25-Sep-17 Hamilton, Canada Early Stage VC cancer cells. 46.00 Biotech Developer of therapeutic drugs for rare diseases, such as desmoid tumors, Bain Capital, SpringWorks neurofibromatosis, hereditary xerocytosis, and post-traumatic stress OrbiMed, LifeArc, Therapeutics 25-Sep-17 Baltimore, MD Early Stage VC disorder. 103.00 Pfizer

Syncona, Woodford Investment Management, Cormorant Asset Management, London, United Developer of T-cell immunotherapy products intended for the treatment Nextech Invest, Autolus 26-Sep-17 Kingdom Later Stage VC of cancer. 80.00 Arix Bioscience

Source: Pitchbook Compiled by: Lea Keller and Morgan Reape 16 Monthly Healthcare Review September 2017 Private Equity Placements and Venture Capital Rounds The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month. Last Last Financing Company Name Financing HQ Location Round Description Investor(s) Size Date (Millions) Developer of antibiotics intended for microbiome precision-editing and Khosla Ventures, Eligo Bioscience 26-Sep-17 Paris, France Early Stage VC bacteria-associated diseases. 20.00 Seventure Partners Newron Pharmaceuticals Provider of pharmaceutical products intended to develop novel therapies Undisclosed (NWRN) 26-Sep-17 Milan, Italy PIPE for pain and for diseases of the central nervous system. 27.97 Investors The Cronos Group Undisclosed (MJN) 26-Sep-17 Toronto, Canada PIPE Distributor of medical cannabis. 11.90 Investors

Born2Grow, High- Tech Gründerfonds, Venneos Developer of a silicon-chip-based imaging system designed to analyze Beteiligungs, Max Venneos 26-Sep-17 Stuttgart, Germany Early Stage VC biological cells. Undisclosed Planck Innovation Developer of a cardiac monitoring device using advanced signal processing techniques and machine-learned algorithms to reveal previously hidden information about a patient's health status from within their physiological Undisclosed Analytics for Life 27-Sep-17 Kingston, Canada Angel signals in the coronary artery. 19.84 Investors TPG Biotech, Adage Capital Management, Developer of a new drug-device combination therapy for people who Lifescivc, Lumira Engage Therapeutics 27-Sep-17 Summit, NJ Early Stage VC experience uncontrolled epileptic seizures. 23.00 Capital

Source: Pitchbook Compiled by: Lea Keller and Morgan Reape 17 Monthly Healthcare Review September 2017 Private Equity Placements and Venture Capital Rounds The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month. Last Last Financing Company Name Financing HQ Location Round Description Investor(s) Size Date (Millions)

Mark Tompkins and Katalyst Securities, AbbVie Ventures, William Gates, Eric Lefkofsky, Craig Mundie, Patrick G. Ryan, David Walt, Developer of immunomodulatory and gene silencing drugs for the Undisclosed Exicure 27-Sep-17 Skokie, IL Later Stage VC treatment of inflammatory disorders. 20.00 Investors Developer of drugs created to target obesity and associated Seventure Partner, cardiometabolic diseases through an action on the gut microbiota and the Undisclosed LNC Therapeutics 27-Sep-17 Bordeaux, France Later Stage VC intestinal membrane. 7.68 Investors

Developer of autoantibody assay technologies that stratify indeterminate Nottingham, United pulmonary nodules for the risk of malignancy, enabling doctors to perform Undisclosed Oncimmune (ONC) 27-Sep-17 Kingdom PIPE a blood test to assess risk and detect lung cancer in its early stages. 6.48 Investors Advanced Proteome Developer of anti-cancer therapeutics that exploit the properties of a Undisclosed Therapeutics (APTCF) 28-Sep-17 Boston, MA PIPE natural human protein. 0.64 Investors Developer of an automated lung diagnostic system created to monitor the state of chronic disease and enable patients to control their lung condition Lung Passport 28-Sep-17 Minsk, Belarus Early Stage VC and detect respiratory diseases early on. 0.10 Spacemind Capital Abiomed, Pitango Venture Capital, Developer of a temporary venous catheter-based therapy created to treat Jafco, Jacques Magenta Medical 28-Sep-17 Ashkelon, Israel Early Stage VC acute decompensated heart failure. 15.00 Seguin Midatech Pharma Abingdon, United Manufacturer of pharmaceuticals focused on oncology and other Undisclosed (MTPH) 28-Sep-17 Kingdom PIPE therapeutic areas. 10.37 Investors

Source: Pitchbook Compiled by: Lea Keller and Morgan Reape 18 Monthly Healthcare Review September 2017 Private Equity Placements and Venture Capital Rounds The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month. Last Last Financing Company Name Financing HQ Location Round Description Investor(s) Size Date (Millions)

Provider of artificial intelligence imaging technology that offers medical Tencent, Sequoia images, data analytics, and decision support through cutting-edge machine Capital, United VoxelCloud 28-Sep-17 Los Angeles, CA Early Stage VC learning and validation from massive, real-world training data. 15.00 Capital Investment Developer of a wearable technology platform that uses neuroscience to London, United improve sleep as the gateway to enhanced cognitive functioning and Deep Knowledge DeepWave 29-Sep-17 Kingdom Seed Round health. Undisclosed Ventures PE Growth/ Developer of next-generation products to address unmet medical needs of Undisclosed Geno 29-Sep-17 Cocoa, FL Expansion patients with a variety of pulmonary and cardiac diseases. 29.94 Investors Peter Thiel, Stefan Roever, BlueTree Allied Angels, Developer of a technology platform for designing novel peptide antibiotics Undisclosed Peptilogics 29-Sep-17 Pittsburgh, PA Early Stage VC that inactivate drug-resistant bacteria for rapid selection. 5.50 Investors

Source: Pitchbook Compiled by: Lea Keller and Morgan Reape 19 Monthly Healthcare Review September 2017 Mergers and Acquisitions The following table includes mergers and acquisitions for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Transaction Acquirer Target HQ Location Date Description Value (Millions) Developer of gene modification and cell delivery technology to shield and strengthen the immune system to create enduring and life-long protection for individuals living with a broad range of debilitating and currently incurable CSL Calimmune Tucson, AZ 1-Sep-17 diseases. 416.00

Developer of an online healthcare platform that provides medicine and related 1mg Dawailelo Varanasi, India 1-Sep-17 medical supplies based on the prescribed reports of healthcare professionals. Undisclosed Provider of patient outreach adherence calls and prescription home delivery to QPharma MedStart Connect San Diego, CA 1-Sep-17 support continuing medication adherence. Undisclosed Nexeon Developer of technologies and applications that interface with the nervous system Medsystems to treat a variety of diseases, including atrial fibrillation, overactive bladder, and Nexeon MedSystems Belgium Isnes, Belgium 1-Sep-17 brain cancers. Undisclosed Developer and marketer of nuclear pharmaceuticals used for both diagnostic and Jubilant Draximage Triad Isotopes Orlando, FL 1-Sep-17 imaging procedures. Undisclosed Diaxonhit GenBio San Diego, CA 5-Sep-17 Developer, manufacturer, and marketer of immunoassay products. 2.00 Provider of researching tools and equipment intended for exploring DNA damage Bio-Techne Trevigen Gaithersburg, MD 5-Sep-17 and repair in relation to cancer research. Undisclosed

Provider of high-value data, analytics, and technology services intended to deliver strategic market data insights and help professionals understand the full market lifecycle, from predictive market analysis to patient influence, physician PRA Health Sciences Symphony Health Conshohocken, PA 6-Sep-17 prescribing, pharmacy fulfillment, payer reimbursement, and sales compensation. 530.00 Developer of small molecule drugs targeting the innate immune system for the Bristol-Myers Squibb IFM Therapeutics Boston, MA 7-Sep-17 treatment of cancer, autoimmunity, and inflammatory disorders. 2320.00 Paddington, Citadel Group Charm Health Australia 15-Sep-17 Provider of specialist oncology electronic medical record systems. 6.49 Houghton-Le- Houghton Spring, United Christie & Co Pharmacy Kingdom 15-Sep-17 Provider of medication and pharmaceutical products. Undisclosed

Source: Pitchbook Compiled by: Lea Keller and Morgan Reape 20 Monthly Healthcare Review September 2017 Mergers and Acquisitions The following table includes mergers and acquisitions for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Transaction Acquirer Target HQ Location Date Description Value (Millions)

Developer of pharmaceutical therapeutics designed to treat serious rare diseases, Opexa Therapeutics Acer Therapeutics Cambridge, MA 19-Sep-17 including vascular ehlers-danlos syndrome and urea cycle disorders. Undisclosed The Woodlands, Provider and developer of patient-specific cellular therapies for the treatment of Acer Therapeutics Opexa Therapeutics TX 19-Sep-17 autoimmune diseases. Undisclosed InfaCare Mallinckrodt Pharmaceuticals Trevose, PA 25-Sep-17 Manufacturer of a pharmaceutical drug for the treatment of neonatal jaundice. 425.00

MoneyTrac Technology PotSaver San Diego, CA 27-Sep-17 Producer of cannabis products for local dispensaries and shops. Undisclosed Alberta Green Ravencrest Resources Biotech Edmonton, Canada 28-Sep-17 Producer of medical marijuana. 0.94 Venus Saol International BioTherapeutics Seattle, WA 28-Sep-17 Provider of biotechnology products and services. 74.50

Source: Pitchbook Compiled by: Lea Keller and Morgan Reape 21